JSM Activity #307This is the preliminary program for the 2004 Joint Statistical Meetings in Toronto, Canada. Currently included in this program is the "technical" program, schedule of invited, topic contributed, regular contributed and poster sessions; Continuing Education courses (August 7-10, 2004); and Committee and Business Meetings. This on-line program will be updated frequently to reflect the most current revisions. To View the Program: You may choose to view all activities of the program or just parts of it at any one time. All activities are arranged by date and time. |
|
The views expressed here are those of the individual authors and not necessarily those of the ASA or its board, officers, or staff. Back to main JSM 2004 Program page |
Legend: = Applied Session,
= Theme Session,
= Presenter FRY = Fairmont Royal York, ICH = InterContinental Hotel, TCC = Metro Toronto Convention Center |
||
307 | Wed, 8/11/04, 8:30 AM - 10:20 AM | TCC-701 B |
Design Issues - Contributed - Papers | ||
Biopharmaceutical Section, Biometrics Section, ENAR | ||
Chair(s): Sarah J.H. Kogut, Medtronic Neurological | ||
8:35 AM | Goodness of Fit of Relative Survival Models — Janez Stare, Univerza v Ljubljani, Slovenija; Maja Pohar, Univerza v Ljubljani, Slovenija; Robin Henderson, University of Lancaster | |
8:50 AM | Rank-based Estimate of Four-parameter Logistic Model with Application in Pharmaceutical Sciences — Kimberly Crimin, Pfizer Inc.; Thomas Vidmar, Pfizer Inc.; Joseph McKean, Western Michigan University | |
9:05 AM | On Selecting among Treatments with Binomial Outcomes — Elena M. Buzaianu, Syracuse University; Pinyuen Chen, Syracuse University | |
9:20 AM | Comparison of Analyses for Repeated Measurements from Ophthalmic Data — Kuolung Hu, Eli Lilly and Company; Vipin K. Arora, Eli Lilly and Company; David Manner, Southwestern Medical School | |
9:35 AM | On Semiparametric Transformation Cure Models — Wenbin Lu, North Carolina State University; Zhiliang Ying, Columbia University | |
9:50 AM | Drug-drug Interaction Study of an Antimigraine Agent and Erythromycin — Meiyu Shen, U.S. Food and Drug Administration; Stella G. Machado, U.S. Food and Drug Administration | |
10:05 AM | A Stopping Plan for a Bioequivalence Study — Shu-Ping Lan, Pfizer Inc. | |
JSM 2004
For information, contact jsm@amstat.org
or phone (888) 231-3473. If you have questions about the Continuing Education program,
please contact the Education Department. |